Skip to main content
OpenTrials
Completed

NCT Number: NCT06910098

Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Completed

Looking for future studies?

Notify Me

Key information

Conditions

LDL - Low Density Lipoprotein Receptor Disorder Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dyslipidemias Genetic Diseases, Inborn Hyperlipidemias Hyperlipoproteinemia Type II Hyperlipoproteinemias Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Metabolic Diseases Metabolism, Inborn Errors Nutritional and Metabolic Diseases Rosuvastatin

Age range

30 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Central Park Teaching Hospital

Lahore, 54600, Pakistan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients who were already on statins

Exclusion criteria

hereditary diseases including familial hypercholesterolemia and kidney diseases

Treatment and study plan

Rosuvastatin

Drug

a dose of 5mg were given and were compared for the cpk, ast and ldl levels

Primary outcomes

  1. impact of rosuvstatin over LDL, CPK and AST levels

    Time frame: 12 weeks

    Pre- and post intervention levels of fasting serum low-density lipoprotein (LDL) in mg/dL were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin.

  2. impact of rosuvstatin over LDL, CPK and AST levels

    Time frame: 12 weeks

    Pre- and post-intervention levels of creatine phosphokinase (CPK) in mcg/L were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin in terms of rhabdomyolysis.

  3. impact of rosuvstatin over LDL, CPK and AST levels

    Time frame: 12 weeks

    Pre- and post-intervention levels of Aspartate Aminotransferase (AST) in U/L were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin in terms of liver damage.

Sponsors and collaborators

Lead sponsor

Central Park Medical College

Other

Registry information

Official study title

Assessment of Impact of Rosuvastatin Doses on Low Density Lipoprotein Levels, Creatinine Phosphokinase Levels and Aspartate Aminotransferase Levels: A Randomized Controlled Trail

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 4, 2025
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.